IFA
ORIC icon

Invus Financial Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Invus Financial Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$7.12M Hold
1,007,575
– – 7.98% 4
2024
Q1 		$13.9M Hold
1,007,575
– – 11.01% 4
2023
Q4 		$9.27M Hold
1,007,575
– – 7.25% 5
2023
Q3 		$6.1M Hold
1,007,575
– – 3.82% 6
2023
Q2 		$7.82M Hold
1,007,575
– – 4.18% 8
2023
Q1 		$5.74M Hold
1,007,575
– – 3.74% 7
2022
Q4 		$5.93M Hold
1,007,575
– – 3.16% 7
2022
Q3 		$3.22M Hold
1,007,575
– – 1.77% 8
2022
Q2 		$4.51M Hold
1,007,575
– – 2.73% 7
2022
Q1 		$5.38M Hold
1,007,575
– – 2.39% 7
2021
Q4 		$14.8M Hold
1,007,575
– – 4.5% 7
2021
Q3 		$21.1M Hold
1,007,575
– – 5.64% 7
2021
Q2 		$17.8M Hold
1,007,575
– – 3.55% 7
2021
Q1 		$24.7M Hold
1,007,575
– – 5.66% 6
2020
Q4 		$34.1M Sell
1,007,575
-1
-0% -$29 14.26% 5
2020
Q3 		$25.2M Hold
1,007,576
– – 12.12% 5
2020
Q2 		$34M Buy
+1,007,576
New +$32.2M 12.28% 4

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invus Financial Advisors's ORIC Position: Q2 2024 in Review

Invus Financial Advisors held its Oric Pharmaceuticals (ORIC) position steady in Q2 2024 at 1,007,575 shares worth $7.12M. The position accounts for 7.98% of the portfolio, ranked #4.

Invus Financial Advisors first reported a position in ORIC in Q2 2020 and has held it in 17 quarters since. The position peaked at $34.1M in Q4 2020. 113 funds tracked by Wall St. Rank hold ORIC as of Q2 2024.

  • Invus Financial Advisors held 1,007,575 shares of Oric Pharmaceuticals worth $7.12M as of Q2 2024.
  • Invus Financial Advisors left its Oric Pharmaceuticals share count unchanged in Q2 2024.
  • Oric Pharmaceuticals made up 7.98% of Invus Financial Advisors's portfolio in Q2 2024, its #4 holding.
  • Invus Financial Advisors first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 17 quarters since.
  • Invus Financial Advisors's Oric Pharmaceuticals position peaked at $34.1M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2024.

Based on Invus Financial Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.